Promore Pharma
STOCKHOLM, SE / ACCESSWIRE / November 16, 2021 / Promore Pharma (STO:PROMO) (FRA:8T0)
Promore Pharma AB (publ) today announced the composition of the Nomination Committee for the Annual General Meeting 2022, which will be held on Tuesday 17 May 2022. The Nomination Committee shall, according to decided principles for the appointment of the Nomination Committee, consist of the Chairman of the Board and representatives for the three largest shareholders in the company.
The main task of the Nomination Committee is to submit proposals for Chairman of the Board and other members of the Board, remuneration for Board work, the election and remuneration of auditors. The Nomination Committee shall be composed of the Chairman of the Board and members appointed by the three largest shareholders in the company based on ownership of the Company as per the end of September 2021.
Accordingly, the following committee members have been appointed:
- Göran Pettersson, Chairman of the Board
- David Sundin, representing Corespring New Technology AB (former Midroc New Technology)
- Henric Rahm, representing PharmaResearch Co. Ltd
- Hans-Peter Ostler, representing a co-registered group of shareholders, with an ownership equivalent to 8.2% of the company
The Nomination Committee's proposals will be presented in the Notice to the AGM 2022 and on the company web site, www.promorepharma.com. Shareholders desiring to submit comments or proposals to the nomination committee can send them via email to info@promorepharma.com.
For additional information, please contact
Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com
Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: erik.magnusson@promorepharma.com
Promore Pharmas Certified Adviser is Erik Penser Bank
Tel: [+46] 8-463 83 00
E-mail: certifiedadviser@penser.se
Promore Pharma in brief
Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma's two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.
SOURCE: Promore Pharma
View source version on accesswire.com:
https://www.accesswire.com/673114/Nomination-Committee-Appointed-for-the-Annual-General-Meeting-2022-in-Promore-Pharma
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Camino Completes C$5.6 Million Investment with Strategic Investors17.11.2025 12:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / November 17, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC:CAMZF) ("Camino" or the "Company") is pleased to announce the closing of its -brokered private placement (the "Financing") of common shares in the capital of the Company (the "Shares") previously announced in its news release dated November 12, 2025. Under the Financing, the Company issued an aggregate of 15,554,666 Shares at an issue price of $0.36 per Share, for aggregate gross proceeds of C$5,599,680. Participants in the Financing included two new key shareholders, Elemental Royalties (formerly EMX Royalty Corp.) and Continental General Insurance Company, as well as certain insiders of Camino. The gross proceeds of the Financing will be applied towards corporate working capital, legal expenses, engineering studies, project development, and general administrative expenses. The Shares issued pursuant to the Financing are subject to a statutory hold period expiring on March 15, 2026, in acc
GA-ASI Completes Full-Scale Fatigue Test on MQ-9B17.11.2025 03:10:00 CET | Press release
MQ-9B's Third Lifetime Test Completes the FSF Testing Process With a Total of 120,000 Hours DUBAI, UAE / ACCESS Newswire / November 16, 2025 / On October 31, 2025, General Atomics Aeronautical Systems, Inc. (GA-ASI) completed its "third lifetime" of full-scale fatigue (FSF) testing for the MQ-9B Remotely Piloted Aircraft (RPA). Completion of FSF testing for the third and final lifetime includes a total of 120,000 operating hours (40,000+ flight hours per aircraft life) for the RPA and is a key milestone in validating the design of the airframe. The testing verifies the airframe structural integrity in support of certification to the NATO STANAG 4671 standard. The aim of the testing is to identify any potential structural deficiencies ahead of fleet usage and assist in developing inspection and maintenance schedules for the airframe. Test results will be used as documentation for certification and will form the basis for in-service inspections of structural components. "The completion o
GA-ASI and Saab Will Demonstrate AEW&C on MQ-9B in 202617.11.2025 03:05:00 CET | Press release
Two Aerospace Leaders Are Bringing Airborne Early Warning and Control to UAS DUBAI, UAE / ACCESS Newswire / November 16, 2025 / Following their announcement to bring Airborne Early Warning and Control (AEW&C) capability to the world's leading Remotely Piloted Aircraft (RPA) platform, General Atomics Aeronautical Systems, Inc. (GA-ASI) and Saab will now team up to demonstrate the capability in the summer of 2026. The demo will be conducted at GA-ASI's Desert Horizon flight operations facility in Southern California using a GA-ASI MQ-9B equipped with AEW&C supplied by Saab. In partnership with Saab, a leading company in AEW&C systems, GA-ASI is pairing Saab's AEW sensors with the world's longest-range, highest-endurance RPA, the MQ-9B. At sea or over land, adding AEW capabilities on MQ-9B enables persistent air surveillance and enables AEW in areas of the world where it doesn't currently exist or is unaffordable, such as for navy aircraft carriers at sea. "Adding AEW&C to the MQ-9B bring
Doha Tattoo Festival Announced as Ticket Sales Officially Open16.11.2025 12:45:00 CET | Press release
DOHA, QA / ACCESS Newswire / November 16, 2025 / Under the patronage of His Excellency Sheikh Khalifa bin Hamad bin Khalifa Al Thani, Minister of Interior and Commander of the Internal Security Force (Lekhwiya), the first edition of the Doha International Music and Marching Festival (Doha Tattoo) will be held from 16 to 20 December 2025 at Katara Cultural Village. A press conference held at Katara Cultural Village unveiled the line-up of participating bands and ticket details, attended by members of the Doha Tattoo organising committee and partner representatives. The Doha Tattoo will combine precision with musical artistry, showcasing performances by distinguished musical bands from seven countries: the United Kingdom, the United States of America, Turkia, Hashemite Kingdom of Jordan , the Sultanate of Oman, Kazakhstan, and the State of Qatar. The participating line-up includes the Irish Guards and the Royal Air Force Music Services from the United Kingdom, the United States Air Force
Pet-Food Revolution: Two New Global Surveys Reveal Growing Guardian Openness to Sustainable Diets for Dogs and Cats14.11.2025 15:05:00 CET | Press release
LONDON, UK / ACCESS Newswire / November 14, 2025 / Two pioneering studies published in the journal Animals have explored in depth how dog and cat guardians perceive more sustainable pet food options. Led by Jenny L. Mace, Alexander Bauer, Andrew Knight and Billy Nicholles, the research sheds new light on the potential for alternative proteins and plant-based diets in the companion animal sector. Study 1 - Dogs: ‘Consumer Acceptance of Sustainable Dog Diets: A Survey of 2,639 Dog Guardians' In the first study, the team surveyed 2,639 dog guardians worldwide. Around 84% of respondents were currently feeding their dogs either conventional or raw meat-based diets. However, a substantial 43% of this group reported they would nevertheless consider at least one type of more sustainable dog food (such as vegan, vegetarian or cultivated-meat formulations). Among the alternative options, the most acceptable was cultivated meat-based dog food (chosen by 24% of these respondents), compared to vege
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom